I-MAB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.57 EUR | -0.63% |
|
-1.26% | -5.99% |
| Jun. 06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
| Jun. 05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 815B | ||||||
| 641B | ||||||
| 352B | - | - | - | - | ||
| 314B | ||||||
| 303B |
- Stock Market
- Equities
- IMAB Stock
- 0VY Stock
- Charts I-Mab
- Sector Chart
